Medicilon Events

Medicilon's preclinical research services cover pharmacodynamic research, drug safety evaluation, pharmacokinetic research, bioanalysis, etc. The establishment of a complete gene therapy R&D platform can provide one-stop services for research on pharmacological efficacy, biodistribution and safety evaluation of cell and gene therapy products.

Looking back at Medicilon 2022, even the most extraordinary days never stop moving forward. Because there is always light guiding us to move forward; there is always love, shining for a long time. Thank you for the moments and memories that link us together. This accumulates as the strength to forge ahead in the New Year.

The 27th Annual Chinese Biopharmaceutical Association (CBA) Meeting will be held on December 17, 2022, at the Marriott Washingtonian Center in Maryland!

Shanghai Medicilon Inc. (Medicilon), as a one-stop pharmaceutical preclinical R&D service platform in China, was once again selected as one of the "Top 20 Chinese R&D CRO Enterprises in 2022" by virtue of its solid R&D strength. This is the 3rd consecutive year that Medicilon has won this honorary title!

The Medicilon translational medicine platform has an experienced professional technical team, starting from the mechanism of action of drug targets and the clinical application of biomarkers, based on the discovery and validation of biomarkers, combining a variety of different technology platforms and state-of-art instruments, and creating multiple bioanalytical methods, to reduce the cost and time of drug R&D, and provide diverse and efficient services for different types of drugs, different kinds of pharmaceutical companies and projects at different R&D stages.

Christmas is coming up! Wishing you all the Hope, Wonder, and Joy! Have a delicious time!

Medicilon Antibody Development Technical Service is here to help you develop new drugs with high cost performance, high efficiency and high quality.

On December 4th, with the completion of the last concrete pouring, the expansion project of the drug research and development laboratory of Shanghai Medicilon Inc has been completed. This marks the further strengthening of Medicilon's one-stop biopharmacetical preclinical R&D service platform capabilities.

​Recently, Shanghai Medicilon Inc. (Medicilon) signed a strategic collaboration agreement with Infinite Intelligence Pharma (IIP).

On November 10, 2022, the Listed Companies Association of Shanghai held the 4th member meeting of the association and the 1st meeting of council of the association through the online platform of East Money information. The meeting was presided over by Yuan Yi, Secretary of the Association, and supervised by the Shanghai Oriental Notary Public Office.

Medicilon offer a full range of chemistry Research services covering all phases of your project requirements, and clients can work with us under either the FFS (project-based payment) or FTE (full-time equivalent service) models.

On August 29, 2022, Beijing Peptide Biomedical Technology Co., Ltd. (Bejing Peptide) ZT002 injection was approved by the Australian Human Research Ethics Committee for Phase I clinical trials.